CopyPastehas never been so tasty!

The Pharmaceutical Market : Norway

by anonymous

  • 0
  • 0
  • 0
56 views

The macroenvironment for the Norwegian pharmaceutical industry is improving. Politically, the centre-left coalition is expected to hold together at least until the general election in September 2013, but the risk of the coalition breaking up has grown. Economically, the recession was far less pronounced in Norway than in most other European countries and economic recovery is now strengthening. Legally, laws on intellectual property and patent provision are in line with WTO/TRIPS regulations. However, Norway remains on the USTR’s Watch List in 2011 for concerns over patent protection. Demographically, the population is ageing, increasing demand for pharmaceuticals in the near term. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/the-pharmaceutical-market-norway.html

The introduction of international reference pricing has had a moderating effect on Norwegian pharmaceutical price levels, and a step-price system for off-patent drugs has ensured that prices for all generics have fallen. Important steps towards cost-containment have also been taken for reimbursable pharmaceuticals, including the use of a first-choice system. A report by the Business Research Foundation (SNF) has shown that Norwegian pharmaceutical prices are among the lowest in Western Europe. Therefore, market growth is a result of increased consumption, largely due to the ageing population and the introduction of new drugs on the market. Norway is receptive to new drugs, as long as they are cost-effective and have proven therapeutic benefits.

Although Norway is not part of the European Union, the process for pharmaceutical registration has been aligned to EU regulations. The regulatory reforms made the centralised procedure mandatory for all new active substances, and all drugs in a number of drug categories, including all biotech products. In May 2011, PCI Biotech reported that it had been awarded a BIA grant from the Research Council of Norway for the project “immunological effects of photochemical internalisation – local treatment of cancer with metastasis”. The project was initiated in the third quarter of 2011, and will run for three years.

PROVIDING STRATEGIC MARKET ANALYSIS EVERY MONTH
Espicom's highly-regarded world pharmaceutical market research reports provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Market size and trends impacting the development of the market.
Five-year projections for market indicators such as health spending.
Regulations on drug applications & approvals, pricing & reimbursement as well as wholesaling and retail.
Specialised intelligence on generics and biological medicines.
Foreign and local company profiles
 

EXECUTIVE SUMMARY...... 1
Snapshot: Strategic Espicom Analysis.....2
Snapshot: Key Data Projections.3
MACROENVIRONMENT .... 4
POLITICAL....4
ECONOMIC ..5
Projections ....5
LEGAL....6
Norway Remains on the USTR’s Watch List in 2011 6
EU Supplementary Protection Certificates.6
EU Data Exclusivity.....6
DEMOGRAPHIC .7
Projections ....7
Latest Figures7
Demographic Indicators...8
Birth Rate . 8
Death Rate...... 8
Infant Mortality .... 8
Life Expectancy at Birth.... 8
EPIDEMIOLOGY... 9
DISEASE BURDEN.....9
DISEASE PREVALENCE..10
Communicable Diseases.10
HIV/ AIDS 10
Non-Communicable Diseases ......10
Cancer..... 10
Diabetes. 10
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS ..11
NATIONAL AUTHORITIES ....11
Ministry of Health and Care Services. 11
Norwegian Institute of Public Health ...... 11
ORGANISATION......11
The State 11
Regions... 11
Municipalities...... 12
EXPENDITURE..13
Projections ..13
Latest Figures.....14
Fees and Financing...15
Out-of-Pocket Payments. 16
Pharmaceutical Costs......17
INFRASTRUCTURE..18
Hospital Infrastructure ...18
SERVICES....19
Hospital Inpatient Services ...19
Ambulatory Services21
WORKFORCE... 22
Projections ..22
Physicians....23
Dentists 24
Pharmacists.24
REGULATORY AFFAIRS ... 25
EU REGULATORY AUTHORITY.. 25
NATIONAL AUTHORITIES ... 25
MARKETING REGISTRATION......26
EU Marketing Registration....26
Centralised Procedure.....26
National Procedures.26
Marketing Authorisations......26
PROMOTION ....27
Advertising .27
PRICING & REIMBURSEMENT 28
PRICING..... 28
Step-Price System (Trinnpris)29
First-Choice System..29
Out-of-Pocket Payments 29
REIMBURSEMENT . 30
DISTRIBUTION CHANNELS.... 31
DRUG WHOLESALING...31
Leading Wholesalers31
Apokjeden Distribusjon..32
Holtung..32
Norsk Medisinaldepot (NMD) ......32
DRUG RETAILING...... 33
Pharmacies..33
Leading Pharmacy Chains .....34
MARKET ANALYSIS... 35
SIZE......35
Projections ..35
Historical Figures......36
Current Structure......37
Parallel Imports .40
PRODUCT DEVELOPMENT..41
National Research and Development.41
Clinical Trials ......42
MANUFACTURING..43
Employees...43
TRADE 44
Exports .44
Imports.47
Balance of Trade 51
COMPETITION.... 52
TRADE ASSOCIATION....53
LMI....53
COMPANY INTELLIGENCE.. 54
Axellia Pharmaceuticals..54
Fresenius Kabi Norge54
Nycomed Pharma......54
Weifa54
OTC PHARMACEUTICALS 55
DISTRIBUTION CHANNELS..55
MARKET SIZE... 56
COMPETITION. 58
GENERIC PHARMACEUTICALS ..... 59
REGULATORY AFFAIRS .59
EU Marketing Registration....59
PRICING & REIMBURSEMENT....59
Generic Substitution59
MARKET SIZE....59
BIOLOGICS & BIOSIMILARS...60
REGULATION... 60
EU Approval Process.60
EU Regulation of Biosimilars 60
EMA Guideline Documents....61
National Regulation.61
Norway Removes Biosimilar Filgrastim from its Switchable Products List ...... 61
COMPETITION. 62
Trade Association .....62
NBA ..62
Company Intelligence.....63
Affitech...63
Algeta .....63
Algipharma...63
Avexxin...63
Bionor Pharma....63
Biotec Pharmacon.....63
Clavis Pharma......64
Epitarget64
FMC BioPolymer.64
LAURAS ..64
Lytix Biopharma .65
PCI Biotech....65
Pronova BioPharma Norge....65
Santosolve....65
siRNAsense...65
Spermatech..65
CONCLUSIONS: OPPORTUNITIES & CHALLENGES .66
Strategic Espicom Analysis 66
MACROENVIRONMENT....66
EPIDEMIOLOGY..66
HEALTHCARE......66
REGULATORY AFFAIRS.....67
PRICING & REIMBURSEMENT.67
DISTRIBUTION CHANNELS .....68
MARKET68
COMPETITION ....69
OTC PHARMACEUTICALS.69
GENERIC PHARMACEUTICALS69
BIOLOGICS & BIOSIMILARS....69
Radar Analysis.71
SWOT Analysis.71
DIRECTORY . 72
GOVERNMENT ORGANISATIONS.... 72
PHARMACEUTICAL COMPANIES..... 72
Biologic Companies..72
PHARMACEUTICAL DISTRIBUTORS 72
PHARMACY CHAINS..... 72
TRADE ORGANISATIONS.... 72

List of Tables
Espicom Analysis of the Pharmaceutical Market, 2012.2
Key Data Projections, 2012-20173
Political Landscape, 2012....4
Regional Ranking of Projected Economies, 2017...5
Projected Economy, 2012-2017..5
Regional Ranking of Projected Demographics, 2017....7
Projected Demographics, 2012-20177
Demographic Indicators, 2003-20098
Causes of Death, 2008-2009......9
Regional Ranking of Projected Health Expenditure, 2017..13
Projected Health Expenditure, 2012-2017......13
Health Expenditure by Function of Care, 2006-2008 (NOK Millions)......14
Health Expenditure on Medical Goods Dispensed to Outpatients, 2006-2008 (NOK Millions) .14
Out-of-Pocket Payments for Healthcare Services, 2010 (NOK).16
Number of Beds by Type of Institution, 2007-2009.....18
Hospital Activity, 2004-2009...19
Discharges from General Hospitals by Diagnosis, 2007-2008..19
General Hospital Day Cases by Diagnosis, 2007-200820
General Hospital Outpatient Consultations by Diagnosis, 2007-2008....21
Regional Ranking of Projected Physicians, 2017..22
Projected Physicians, 2012-2017.....22
Physicians by Specialty, 2008...23
Dentists & Other Dentistry Staff, 2004-200824
Pharmacy Staff by Category, 2008-2009......24
Active Ingredients, Medicinal Products and Marketing Authorisations, 2003-2009 ..26
Pharmacy Chains and Wholesalers, 2009....31
Number of Pharmacies by Ownership, 200933
Regional Ranking of Projected Pharmaceutical Markets, 201735
Projected Pharmaceutical Market at Retail Prices, 2012-2017..35
Historical Pharmaceutical Market at Retail Prices, 1995-2011..36
Pharmaceutical Market by Type at Retail Prices, 2009......37
Pharmaceutical Sales by Therapeutic Group at Wholesale Prices, 2007-2009 (NOK Millions) ..38
Top 25 Products by Sales at Wholesale Prices, 2009...39
Parallel Imported Drug Sales, 1995-2009.....40
R&D Expenditure, 2000-2008..41
Ongoing Clinical Trials in the Pharmaceutical Industry by Phase, 2008.42
Pharmaceutical Production, 1998-201043
Pharmaceutical Exports by Category, 1995-2010 (US$000s)....44
Pharmaceutical Exports by Country/Region, 2010 (US$000s)..46
Pharmaceutical Imports by Category, 1995-2010 (US$000s)...47
Imports of Raw Materials by Country/Region, 2010 (US$000s)......48
mports of Antisera & Vaccines by Country/Region, 2010 (US$000s).....49
Imports of Medicaments by Country/Region, 2010 (US$000s) 50
Balance of Pharmaceutical Trade, 1995-2010 (US$000s)..51
Top 25 Pharmaceutical Companies by Sales at Wholesale Prices, 2009.52
Member Companies of LMI, 2010...53
OTC Sales by Therapeutic Group at Wholesale Prices, 2007-2009 (NOK Millions) 56
Top 25 OTC Drugs at Wholesale Prices, 2009.57
Top 10 Companies by OTC Sales at Wholesale Prices, 2009......58
Drug and Development Member Companies of NBA, 2010......62
Espicom Analysis of the Pharmaceutical Market, 2012......70
SWOT Analysis of the Pharmaceutical Market, 2012...71

List of Charts
Funding of Pharmaceuticals, 2008 (%)..17
Wholesaler Market Shares, 2009.....31
Pharmacy Market Shares, 2009......34
Regional Comparison of Top 6-16 Projected Pharmaceutical Markets at Retail Prices, 2017 ....36
Historical Pharmaceutical Market at Retail Prices, 1995-2011...37
Investments in R&D by Therapeutic Group, 2008 (%).41
Submitted Clinical Trial Applications, 2002-2009.42
Number of Employees in the Pharmaceutical Industry, 2000-200943
Pharmaceutical Exports, 1995-2010 (US$ Millions).....45
Pharmaceutical Exports by Country/Region, 2010 (%) ......45
Pharmaceutical Imports, 1995-2010 (US$ Millions)....47
Pharmaceutical Imports by Country/Region, 2010 (%).....48
Balance of Pharmaceutical Trade, 1995-2010 (US$ Millions)....51
General Sales Outlets Selling OTC Pharmaceuticals, 2008 (%)..55
Radar Graph of the Pharmaceutical Market, 2012......71

For more information kindly visit :
The Pharmaceutical Market : Norway

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: https://twitter.com/BharatBook
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
http://financemarketreports.blogspot.com/

Add A Comment: